Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
This article is part of a live interview with Dr. Engel, Associate Vice President, Cardiometabolic and Women's Health, Merck Research Laboratories.
Read More »The VERTIS CV Study – SGLT-2 Inhibitors’ Cardiovascular and Renal Outcomes in T2D
The Long-term Cardiovascular Effects of Ertugliflozin in Type 2 Diabetes
Does Ertugliflozin share the same cardiovascular and renal benefits recently demonstrated by other SGLT-2 Inhibitors?
Read More »Amputations are No Longer Listed As a Box Warning For Canagliflozin
The risk for leg and foot amputation is now listed under Warnings and Precautions instead of box warning.
Read More »SGLT-2 vs. GLP-1: Cardiovascular Outcomes in Adults with Type 2 Diabetes
Cardiovascular events decline for patients using which antidiabetic medication?
Read More »Research Highlights Combination Canagliflozin plus Liraglutide Effects on HBA1c
The combination of an SGLT2i plus a GLP-1 RA results in surprising effects on endogenous glucose production and HBA1c.
Read More »Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study
Care of the elderly can be very challenging. Can adding yet another medication actually help?
Read More »SGLT-2 Inhibitors and the Risk for Urosepsis
Are SGLT-2 inhibitors responsible for urosepsis or Fournier's gangrene?
Read More »Adding An SGLT-2 Earlier To A Treatment Plan Yields Positive A1c Levels
If dapagliflozin is the second medication prescribed to the patient after the first-line treatments of metformin or sulfonylurea, it has a greater impact.
Read More »Jardiance Meets EMPEROR-Reduced Primary Endpoint
Diabetes drug shows benefit for heart failure patients with reduced ejection fraction.
Read More »SGLT2 Inhibitors for Kidney Disease
A 56-year old male with type 2 diabetes and stage 3 chronic kidney disease contacted us recently regarding his new prescription for the SGLT2 inhibitor canagliflozin (Invokana)....
Read More »